These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 19124423)

  • 21. Atrial structural remodeling as an antiarrhythmic target.
    Burstein B; Nattel S
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):4-10. PubMed ID: 18594481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Atrial fibrillation and renin-angiotensin system].
    Yamashita T
    Nihon Rinsho; 2007 Mar; 65(3):569-74. PubMed ID: 17354577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non-channel drugs to prevent atrial fibrillation].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Nov; 146(45):2287-94. PubMed ID: 16304807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Atrial fibrillation: potential therapeutic interventions in the renin-angiotensin-aldosterone system].
    Dabrowski R; Szwed H
    Kardiol Pol; 2007 Apr; 65(4):440-5. PubMed ID: 17530565
    [No Abstract]   [Full Text] [Related]  

  • 25. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in atrial fibrillation.
    Levine MJ; Schweitzer P
    Vnitr Lek; 2010 Nov; 56(11):1138-41. PubMed ID: 21247007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation.
    Tsai CT; Lai LP; Hwang JJ; Chen WP; Chiang FT; Hsu KL; Tseng CD; Tseng YZ; Lin JL
    J Hypertens; 2008 Mar; 26(3):570-82. PubMed ID: 18300870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
    Pecini R; Elming H; Pedersen OD; Torp-Pedersen C
    Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atrial fibrillation and heart failure: natural history and pharmacological treatment.
    Savelieva I; John Camm A
    Europace; 2004 Sep; 5 Suppl 1():S5-19. PubMed ID: 15450275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Morphological remodeling in atrial fibrillation].
    Goette A; Lendeckel U
    Herz; 2006 Apr; 31(2):101-7; quiz 142-3. PubMed ID: 16738831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upstream therapy for atrial fibrillation.
    Kumagai K
    Circ J; 2007; 71 Suppl A():A75-81. PubMed ID: 17587744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Innovative therapeutic approach to atrial fibrillation: AT1-receptor blocker].
    Goette A
    Dtsch Med Wochenschr; 2006 Aug; 131(34-35 Suppl 4):S103-7. PubMed ID: 16921445
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system.
    Guo X; Saini HK; Wang J; Gupta SK; Goyal RK; Dhalla NS
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):717-32. PubMed ID: 16076281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrical remodeling in atrial fibrillation.
    Dobrev D
    Herz; 2006 Apr; 31(2):108-12; quiz 142-3. PubMed ID: 16738832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drugs for heart rate control and non-antiarrhythmic drugs in atrial fibrillation].
    Chávez LL
    Arch Cardiol Mex; 2007; 77 Suppl 2():S2-54-S2-58. PubMed ID: 17972380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
    Lévy S
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.
    Huang G; Xu JB; Liu JX; He Y; Nie XL; Li Q; Hu YM; Zhao SQ; Wang M; Zhang WY; Liu XR; Wu T; Arkin A; Zhang TJ
    Eur J Clin Invest; 2011 Jul; 41(7):719-33. PubMed ID: 21250983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atrial fibrillation and atrial fibrosis.
    Tan AY; Zimetbaum P
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):625-9. PubMed ID: 21633248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atrial fibrillation: mechanistic insights and treatment options.
    Mathew ST; Patel J; Joseph S
    Eur J Intern Med; 2009 Nov; 20(7):672-81. PubMed ID: 19818285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of angiotensin II improves hyperthyroid induced abnormal atrial electrophysiological properties.
    Xiao P; Gao C; Fan J; Du H; Long Y; Yin Y
    Regul Pept; 2011 Aug; 169(1-3):31-8. PubMed ID: 21545815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.